Characteristics of FDA drug recalls: A 30-month analysis-Reference-Cited by-同舟云学术

Characteristics of FDA drug recalls: A 30-month analysis

Published:2016-02-15 Issue:4 Volume:73 Page:235-240
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Hall Kelsey¹,Stewart Tyler²,Chang Jongwha³,Freeman Maisha Kelly⁴

Affiliation:

1. Walmart Pharmacy, Louisville, KY

2. Mills Discount Pharmacy, Birmingham, AL

3. Pharmaceutical Social and Administrative Sciences, McWhorter School of Pharmacy, Samford University, Birmingham, AL

4. Pharmacy Practice, Center for Healthcare Innovation and Patient Outcomes Research, McWhorter School of Pharmacy, Samford University, Birmingham, AL

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/73/4/235/28411396/ajhp0235.pdf

Reference21 articles.

1. Centers for Disease Control and Prevention. Multistate outbreak of fungal meningitis and other infections (October23, 2013). www.cdc.gov/hai/outbreaks/meningitis.html (accessed 2015 Mar 10).

2. Nussbaum A . J&J sees significant costs in 2011 to fix recalls (January25, 2011). www.bloomberg.com/news/articles/2011-01-25/j-j-profit-declines-12-on-product-recalls-2011-outlook-trails-forecast (accessed 2015 Mar 10).

3. Carone DA . How a birth control medication recall can lead to high drug costs (March01, 2012). www.kevinmd.com/blog/2012/03/birth-control-medication-recall-lead-high-drug-costs.html (accessed 2015 Mar 10).

4. Gaffney A . Number of drug recalls surges at FDA, led by mid-level concerns(August11, 2014). www.raps.org/Regulatory-Focus/News/2014/08/11/20005/Number-of-Drug-Recalls-Surges-at-FDA-Led-by-Mid-Level-Concerns (accessed 2015 Mar 2).

5. The epidemiology of drug recalls in the United States;Wang;Arch Intern Med,2012

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The continuing challenge of drug recalls: Insights from a ten-year FDA data analysis;Journal of Pharmaceutical and Biomedical Analysis;2024-10

2. A four-year assessment of the characteristics of Rwandan FDA drug recalls;BMC Public Health;2024-07-04

3. Communicating medical device recalls: A rapid review of the literature;Patient Education and Counseling;2024-06

4. Human Medicines Recall Announcements in Saudi Arabia Between 2017 and 2022: An Analysis of Saudi Food and Drug Authority (SFDA) Reports;Therapeutic Innovation & Regulatory Science;2024-03-28

5. Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019;Drug Discovery Today;2023-10